Shockwave Medical

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Shockwave Medical headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Medical Device sector. The company focuses on Biotechnology and has secured $76.6B in funding across 96 round(s). With a team of 1001-5000 employees, Shockwave Medical is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Shockwave Medical, raised $12.5M. Discover more about their projects, partnerships, and impact on our platform.